Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine
US10980881B2 · kind B2 · utility
6Cited by
4References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2018 |
| Grant date | Apr 20, 2021 |
| Priority date | — |
| Expiry date | Jan 10, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/241
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a stable liquid formulation, comprising an antibody or antigen-binding portion thereof, an acetate buffer, glycine, and a surfactant, wherein the stable liquid formulation does not comprise at least one of sugar, a sugar alcohol and a metal salt, and the stable liquid formulation is still stable even upon high antibody content, and is superior in osmolality and viscosity, and subcutaneous administration thereof is possible.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.